CDK19: Cyclin Dependent Kinase 19
A key regulator of transcription and RNA processing, implicated in cancer and developmental disorders.
Gene Information Card
| Symbol | CDK19 |
|---|---|
| Full Name | Cyclin Dependent Kinase 19 |
| Gene Type | Protein coding |
| Chromosomal Location | 6q21 |
| NCBI Gene ID | 23097 ncbi.nlm.nih.gov/gene/23097 |
| Ensembl ID | ENSG00000155111 |
| UniProt ID | Q9BWU1 |
| OMIM ID | 614720 |
| HGNC ID | 19350 |
| Aliases | CDC2L6, CDK11, CDK11B, PITSLRE |
Description
CDK19 (Cyclin Dependent Kinase 19) is a member of the cyclin-dependent kinase family. It is a component of the Mediator complex, which is essential for transcriptional regulation. CDK19 phosphorylates the C-terminal domain (CTD) of RNA polymerase II, thereby influencing transcription initiation and elongation. It also plays a role in RNA processing and cell cycle regulation. Mutations and altered expression of CDK19 have been associated with various cancers and developmental disorders.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Cancer (various types) | Altered expression and mutations in CDK19 can disrupt transcriptional regulation, promoting uncontrolled cell proliferation. | COSMIC, ClinVar |
| Developmental disorders | Germline mutations in CDK19 may affect neurodevelopment and other developmental processes. | OMIM, ClinVar |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Testis | 15.2 | Medium |
| Brain | 8.5 | Low |
| Lung | 6.1 | Low |
| Liver | 4.3 | Low |
| Kidney | 5.0 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HeLa | 12.0 | Cervical cancer cell line |
| K562 | 9.8 | Leukemia cell line |
| A549 | 7.5 | Lung cancer cell line |
| HEK293 | 10.2 | Embryonic kidney cell line |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1135C>T (p.Arg379Trp) | Missense | Rare | Unknown functional effect; reported in ClinVar |
| c.1462G>A (p.Glu488Lys) | Missense | Rare | Unknown functional effect; reported in ClinVar |
| Amplification | Copy number gain | Frequent in some cancers | Potential gain-of-function; associated with increased CDK19 expression |
Mutation functional classification
Loss of Function (LOF)
Loss-of-function mutations in CDK19 are rare but may impair Mediator complex function and transcriptional regulation.
Gain of Function (GOF)
Amplification or overexpression of CDK19 may act as a gain-of-function, promoting oncogenic transcription.
Dominant Negative (DN)
Dominant-negative effects have not been clearly established for CDK19 mutations.
View complete mutation data：
Gene Ontology (GO)
| • GO:0004672 (GO:0004672) | • GO:0005524 (GO:0005524) |
| • GO:0006357 (GO:0006357) | • GO:0006355 (GO:0006355) |
| • GO:0019901 (GO:0019901) |
Pathways
• Mediator complex
• RNA polymerase II transcription
• Cell cycle
Protein Summary
CDK19 is a serine/threonine protein kinase that phosphorylates the C-terminal domain of RNA polymerase II. It is a core component of the Mediator complex, which bridges transcription factors and RNA polymerase II. CDK19 activity is regulated by cyclin binding and phosphorylation. The protein is involved in transcription initiation, elongation, and RNA processing. Its dysregulation is linked to cancer and developmental disorders.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CDK19 Knockout HEK293 Cell Line | EDJ-KQ3695 | Human | 23097 | Details Get a Quote |
| CDK19 Knockout A-549 Cell Line | EDJ-KQ25705 | Human | 23097 | Details Get a Quote |
| CDK19 Knockout HCT 116 Cell Line | EDJ-KQ25706 | Human | 23097 | Details Get a Quote |
| CDK19 Knockout HeLa Cell Line | EDJ-KQ25707 | Human | 23097 | Details Get a Quote |
